The guideline update on the management of rosacea is based on systematic literature and evidence-based reviews of available therapeutic agents and physical modalities.
The efficacy and tolerability of daily cream containing N-butanoyl-l-glutathione (GSH-C4), beta-glycyrrhetinic, and azelaic acid for treatment in patients with mild to moderate rosacea was evaluated.
Epsolay is an investigational topical cream that utilizes the Company’s patented technology process to encapsulate benzoyl peroxide 5% within silica-based microcapsules.
Hypertension, dyslipidemia, and obesity were among the conditions investigators reviewed as being affected by the underlying inflammation associated with rosacea.
Skin redness and other symptoms associated with rosacea were found to improve with the use of a skincare regimen formulated for the treatment of centrofacial erythema.